Tolaney S, et al. MonarcHER: a randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of care chemotherapy in women with HR+, HER2+ advanced breast cancer. Abstract LBA23. ESMO Congress 2019, 29 sept. Barcelona, Spanje.
PARP-remmers: een nieuw tijdperk in de behandeling van (recidiverende) ovariumkanker
aug 2020 | Gynaecologische oncologie